Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny

Stock Track

02/10

Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.

The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.

Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1177836469"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177836469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177836469?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177836469","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.</p><p>The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.</p><p>Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Plummets 5.10% Intraday Amid Patent Lawsuit from Novo Nordisk and Regulatory Scrutiny\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-10 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.</p><p>The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.</p><p>Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1177836469","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177836469","pubTimestamp":1770737085,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘中暴跌5.10%，遭诺和诺德专利诉讼及监管审查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock plummeted 5.10% during intraday trading on Tuesday, extending recent losses as the telehealth company faces a patent infringement lawsuit from Novo Nordisk and regulatory pressure over its compounded weight-loss drug.The decline follows Novo Nordisk's lawsuit filed on Monday, alleging that Hims infringed patents for semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. Hims had launched a $49 compounded version of the medication last week but reversed the launch over the weekend after legal threats from Novo and scrutiny from the U.S. Food and Drug Administration.Analysts have responded by cutting price targets on Hims shares, citing increased legal risks. Deutsche Bank reduced its target to $31 from $42, while Canaccord Genuity slashed its target to $30 from $68, though maintaining a Buy rating on the stock. The legal battle represents a significant challenge for Hims as it expands in the weight-loss market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}